Logo image of RXO

RXO INC (RXO) Stock Fundamental Analysis

USA - NYSE:RXO - US74982T1034 - Common Stock

17.28 USD
-0.13 (-0.75%)
Last: 10/30/2025, 8:04:01 PM
17.28 USD
0 (0%)
After Hours: 10/30/2025, 8:04:01 PM
Fundamental Rating

3

Taking everything into account, RXO scores 3 out of 10 in our fundamental rating. RXO was compared to 42 industry peers in the Ground Transportation industry. RXO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RXO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year RXO was profitable.
RXO had a positive operating cash flow in the past year.
RXO had positive earnings in 4 of the past 5 years.
Of the past 5 years RXO 4 years had a positive operating cash flow.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

1.2 Ratios

RXO's Return On Assets of -9.62% is on the low side compared to the rest of the industry. RXO is outperformed by 76.19% of its industry peers.
RXO's Return On Equity of -19.40% is on the low side compared to the rest of the industry. RXO is outperformed by 71.43% of its industry peers.
RXO has a Return On Invested Capital (0.71%) which is comparable to the rest of the industry.
RXO had an Average Return On Invested Capital over the past 3 years of 6.68%. This is in line with the industry average of 7.72%.
The 3 year average ROIC (6.68%) for RXO is well above the current ROIC(0.71%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -9.62%
ROE -19.4%
ROIC 0.71%
ROA(3y)-1.25%
ROA(5y)1.16%
ROE(3y)-0.55%
ROE(5y)3.28%
ROIC(3y)6.68%
ROIC(5y)7.55%
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

The Operating Margin of RXO (0.38%) is comparable to the rest of the industry.
RXO's Operating Margin has declined in the last couple of years.
The Gross Margin of RXO (16.69%) is worse than 69.05% of its industry peers.
In the last couple of years the Gross Margin of RXO has remained more or less at the same level.
Industry RankSector Rank
OM 0.38%
PM (TTM) N/A
GM 16.69%
OM growth 3Y-45.97%
OM growth 5Y-25.79%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.37%
GM growth 5Y-0.88%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RXO is destroying value.
RXO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, RXO has an improved debt to assets ratio.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 2.79 indicates that RXO is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.79, RXO is doing good in the industry, outperforming 69.05% of the companies in the same industry.
RXO has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
RXO has a Debt to Equity ratio (0.24) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 2.79
ROIC/WACC0.08
WACC9.42%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

RXO has a Current Ratio of 1.35. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.35, RXO is doing good in the industry, outperforming 66.67% of the companies in the same industry.
A Quick Ratio of 1.35 indicates that RXO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, RXO is in the better half of the industry, outperforming 69.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

6

3. Growth

3.1 Past

RXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
RXO shows a strong growth in Revenue. In the last year, the Revenue has grown by 46.41%.
RXO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.69% yearly.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)46.41%
Revenue growth 3Y-1%
Revenue growth 5Y7.69%
Sales Q2Q%52.58%

3.2 Future

The Earnings Per Share is expected to grow by 81.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, RXO will show a quite strong growth in Revenue. The Revenue will grow by 12.22% on average per year.
EPS Next Y9.94%
EPS Next 2Y80.43%
EPS Next 3Y81%
EPS Next 5YN/A
Revenue Next Year28.44%
Revenue Next 2Y17.27%
Revenue Next 3Y13.3%
Revenue Next 5Y12.22%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 144.00 indicates a quite expensive valuation of RXO.
Compared to the rest of the industry, the Price/Earnings ratio of RXO indicates a slightly more expensive valuation: RXO is more expensive than 61.90% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.19. RXO is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 48.26, the valuation of RXO can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as RXO.
When comparing the Price/Forward Earnings ratio of RXO to the average of the S&P500 Index (22.50), we can say RXO is valued expensively.
Industry RankSector Rank
PE 144
Fwd PE 48.26
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100

4.2 Price Multiples

64.29% of the companies in the same industry are cheaper than RXO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.65
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RXO's earnings are expected to grow with 81.00% in the coming years.
PEG (NY)14.48
PEG (5Y)N/A
EPS Next 2Y80.43%
EPS Next 3Y81%

0

5. Dividend

5.1 Amount

No dividends for RXO!.
Industry RankSector Rank
Dividend Yield N/A

RXO INC

NYSE:RXO (10/30/2025, 8:04:01 PM)

After market: 17.28 0 (0%)

17.28

-0.13 (-0.75%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners106.46%
Inst Owner Change0.01%
Ins Owners0.65%
Ins Owner Change0.35%
Market Cap2.83B
Revenue(TTM)5.56B
Net Income(TTM)-308000000
Analysts64.8
Price Target16.52 (-4.4%)
Short Float %7.1%
Short Ratio5.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.59%
Min EPS beat(2)-59.87%
Max EPS beat(2)101.04%
EPS beat(4)3
Avg EPS beat(4)14.53%
Min EPS beat(4)-59.87%
Max EPS beat(4)101.04%
EPS beat(8)7
Avg EPS beat(8)69.32%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.72%
Min Revenue beat(2)-5.04%
Max Revenue beat(2)-2.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.68%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)5.55%
Revenue beat(8)2
Avg Revenue beat(8)-1.09%
Revenue beat(12)2
Avg Revenue beat(12)-2.34%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.63%
PT rev (3m)-3.07%
EPS NQ rev (1m)-22.87%
EPS NQ rev (3m)-18.3%
EPS NY rev (1m)-17.55%
EPS NY rev (3m)-25.24%
Revenue NQ rev (1m)-1.16%
Revenue NQ rev (3m)-5.68%
Revenue NY rev (1m)-1.46%
Revenue NY rev (3m)-4.17%
Valuation
Industry RankSector Rank
PE 144
Fwd PE 48.26
P/S 0.51
P/FCF N/A
P/OCF 404.82
P/B 1.78
P/tB N/A
EV/EBITDA 23.65
EPS(TTM)0.12
EY0.69%
EPS(NY)0.36
Fwd EY2.07%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)0.04
OCFY0.25%
SpS33.9
BVpS9.68
TBVpS-0.07
PEG (NY)14.48
PEG (5Y)N/A
Graham Number5.11
Profitability
Industry RankSector Rank
ROA -9.62%
ROE -19.4%
ROCE 0.9%
ROIC 0.71%
ROICexc 0.72%
ROICexgc 2.36%
OM 0.38%
PM (TTM) N/A
GM 16.69%
FCFM N/A
ROA(3y)-1.25%
ROA(5y)1.16%
ROE(3y)-0.55%
ROE(5y)3.28%
ROIC(3y)6.68%
ROIC(5y)7.55%
ROICexc(3y)7.11%
ROICexc(5y)7.93%
ROICexgc(3y)19.6%
ROICexgc(5y)21.22%
ROCE(3y)8.45%
ROCE(5y)9.55%
ROICexgc growth 3Y-52.22%
ROICexgc growth 5YN/A
ROICexc growth 3Y-56.75%
ROICexc growth 5YN/A
OM growth 3Y-45.97%
OM growth 5Y-25.79%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.37%
GM growth 5Y-0.88%
F-Score4
Asset Turnover1.74
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA 2.82
Cap/Depr 44.83%
Cap/Sales 0.94%
Interest Coverage 0.75
Cash Conversion 5.11%
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z 2.79
F-Score4
WACC9.42%
ROIC/WACC0.08
Cap/Depr(3y)71.18%
Cap/Depr(5y)64.7%
Cap/Sales(3y)1.27%
Cap/Sales(5y)1.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y9.94%
EPS Next 2Y80.43%
EPS Next 3Y81%
EPS Next 5YN/A
Revenue 1Y (TTM)46.41%
Revenue growth 3Y-1%
Revenue growth 5Y7.69%
Sales Q2Q%52.58%
Revenue Next Year28.44%
Revenue Next 2Y17.27%
Revenue Next 3Y13.3%
Revenue Next 5Y12.22%
EBIT growth 1Y-44.74%
EBIT growth 3Y-46.51%
EBIT growth 5Y-20.08%
EBIT Next Year234.95%
EBIT Next 3Y84.92%
EBIT Next 5Y56.44%
FCF growth 1Y-132.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.48%
OCF growth 3YN/A
OCF growth 5YN/A

RXO INC / RXO FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXO.


What is the valuation status of RXO INC (RXO) stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


What is the profitability of RXO stock?

RXO INC (RXO) has a profitability rating of 3 / 10.


What is the financial health of RXO INC (RXO) stock?

The financial health rating of RXO INC (RXO) is 4 / 10.